CNS Pharmaceuticals, Inc.
For the period ended Sep 30, 2025. Filed Nov 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 14, 2025
CNSP$3.94+0.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 1. Financial Statements
| ITEM 1. | FINANCIAL STATEMENTS |
|---|
Balance Sheets
| September 30, 2025 | December 31, 2024 | |
|---|---|---|
| Assets | ||
| Current Assets: | ||
| Cash and cash equivalents | $9,864,087 | $6,461,378 |
| Deferred offering costs | 43,700 | 20,637 |
| Subscription receivable | – | 882,539 |
| Prepaid expenses and other current assets | 1,483,948 | 1,293,954 |
| Total current assets | 11,391,735 | 8,658,508 |
| Noncurrent Assets: | ||
| Prepaid expenses, net of current portion | 474,416 | 36,430 |
| Property and equipment, net | 3,107 | 6,005 |
| Total noncurrent assets | 477,523 | 42,435 |
| Total Assets | $11,869,258 | $8,700,943 |
| Liabilities and Stockholders' Equity (Deficit) | ||
| Current Liabilities: | ||
| Accounts payable and accrued expenses | $1,928,324 | $2,198,260 |
| Notes payable | 30,793 | 326,072 |
| Total current liabilities | 1,959,117 | 2,524,332 |
| Total Liabilities | 1,959,117 | 2,524,332 |
| Stockholders' Equity (Deficit): | ||
| Preferred stock, $0.001 par value, 416,667 shares authorized and 0 shares issued and outstanding | – | – |
| Common stock, $0.001 par value, 25,000,000 shares authorized and 574,580 and 117,796 shares issued and outstanding, respectively | 574 | 118 |
| Additional paid-in capital | 104,229,033 | 90,601,197 |
| Accumulated deficit | (94,319,466) | (84,424,704) |
| Total Stockholders' Equity (Deficit) | 9,910,141 | 6,176,611 |
| Total Liabilities and Stockholders' Equity (Deficit) | $11,869,258 | $8,700,943 |
Statements of Operations
| Three Months Ended | Three Months Ended | Nine Months Ended | Nine Months Ended | |
|---|---|---|---|---|
| September 30, 2025 | September 30, 2024 | September 30, 2025 | September 30, 2024 | |
| Operating expenses: | ||||
| General and administrative | $1,056,560 | $1,383,913 | $3,393,655 | $3,909,928 |
| Research and development | 2,196,828 | 4,244,993 | 6,606,778 | 7,791,967 |
| Total operating expenses | 3,253,388 | 5,628,906 | 10,000,433 | 11,701,895 |
| Loss from operations | (3,253,388) | (5,628,906) | (10,000,433) | (11,701,895) |
| Other income (expenses): | ||||
| Interest income | 37,023 | 25,230 | 118,180 | 33,806 |
| Interest expense | (2,116) | (2,258) | (12,509) | (13,346) |
| Total other income (expense) | 34,907 | 22,972 | 105,671 | 20,460 |
| Net loss | $(3,218,481) | $(5,605,934) | $(9,894,762) | $(11,681,435) |
| Loss per share - basic | $(5.76) | $(153.20) | $(25.60) | $(927.76) |
| Loss per share - diluted | $(5.76) | $(153.20) | $(25.60) | $(927.76) |
| Weighted average shares outstanding - basic | 558,868 | 36,593 | 386,548 | 12,591 |
| Weighted average shares outstanding - diluted | 558,868 | 36,593 | 386,548 | 12,591 |
Statements of Stockholders' Equity (Deficit)
For the three and nine months ended September 30, 2025 and 2024
| Additional · Total | |||||
|---|---|---|---|---|---|
| Common Stock · Paid-in · Accumulated · Stockholders' | |||||
| Shares | Amount | Capital | Deficit | Equity (Deficit) | |
| Balance December 31, 2024 | 117,796 | $118 | $90,601,197 | $(84,424,704) | $6,176,611 |
| Common stock issued for cash, net | 127,582 | 127 | 9,032,894 | – | 9,033,021 |
| Stock cancelled during stock split rounding | (13) | – | (557) | – | (557) |
| Stock-based compensation | – | – | 62,367 | – | 62,367 |
| Net loss | – | – | – | (4,301,320) | (4,301,320) |
| Balance, March 31, 2025 | 245,365 | 245 | 99,695,901 | (88,726,024) | 10,970,122 |
| Common stock issued for cash, net | 27,084 | 27 | 4,505,173 | – | 4,505,200 |
| Stock issued for warrants exercised | 231,964 | 232 | 2,551 | – | 2,783 |
| Stock-based compensation | – | – | 21,841 | – | 21,841 |
| Net loss | – | – | – | (2,374,961) | (2,374,961) |
| Balance, June 30, 2025 | 504,413 | 504 | 104,225,466 | (91,100,985) | 13,124,985 |
| Stock cancelled during stock split rounding | (164) | – | (1,486) | – | (1,486) |
| Stock issued for warrants exercised | 70,331 | 70 | 774 | – | 844 |
| Stock-based compensation | – | – | 18,452 | – | 18,452 |
| Deferred offering costs | – | – | (14,173) | – | (14,173) |
| Net loss | – | – | – | (3,218,481) | (3,218,481) |
| Balance, September 30, 2025 | 574,580 | $574 | $104,229,033 | $(94,319,466) | $9,910,141 |
| Balance December 31, 2023 | 207 | $1 | $65,134,787 | $(69,566,903) | $(4,432,115) |
| Stock issued for cash, net | 74 | – | 3,330,998 | – | 3,330,998 |
| Exercise of warrants | 75 | – | 12,405 | – | 12,405 |
| Stock based compensation | – | – | 202,933 | – | 202,933 |
| Net loss | – | – | – | (3,544,748) | (3,544,748) |
| Balance March 31, 2024 | 356 | 1 | 68,681,123 | (73,111,651) | (4,430,527) |
| Stock issued for cash and warrants, net | 1,507 | 2 | 2,424,411 | – | 2,424,413 |
| Exercise of warrants | 347 | – | 8,921 | – | 8,921 |
| Stock based compensation | – | – | 234,345 | – | 234,345 |
| Stock issued for stock split rounding | 196 | – | – | – | – |
| Net loss | – | – | – | (2,530,753) | (2,530,753) |
| Balance June 30, 2024 | 2,406 | 3 | 71,348,800 | (75,642,404) | (4,293,601) |
| Stock issued for cash and warrants, net | 52,383 | 52 | 12,383,746 | – | 12,383,798 |
| Stock based compensation | – | – | 271,779 | – | 271,779 |
| Stock issued for license agreement | 956 | 1 | 596,301 | – | 596,302 |
| Net loss | – | – | – | (5,605,934) | (5,605,934) |
| Balance September 30, 2024 | 55,745 | $56 | $84,600,626 | $(81,248,338) | $3,352,344 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.